𝗧𝗵𝗿𝗲𝗲 𝗳𝗿𝗼𝗻𝘁𝗶𝗲𝗿 𝗹𝗮𝗯

𝗧𝗵𝗿𝗲𝗲 𝗳𝗿𝗼𝗻𝘁𝗶𝗲𝗿 𝗹𝗮𝗯𝘀 𝗮𝗿𝗲 𝗻𝗼𝘄 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝗻𝗴 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝗽𝗿𝗶𝘇𝗲, and it is not model performance.

Google DeepMind built Isomorphic Labs so AlphaFold would not stay a famous result sitting in a paper.
Anthropic hired the AlphaFold Nobel laureate and shipped Claude Science, a workbench, not a chatbot with a science skin.
OpenAI launched GPT-Rosalind in April, a model built for molecules, proteins, genes, and pathways, gated behind a vetted-access program with Amgen, Moderna, Thermo Fisher Scientific, and the Allen Institute as early partners.
Its partnership with Novo Nordisk is explicit that AI should run end to end, not just discovery, but manufacturing, supply chain, and commercial execution too.
Read together, none of this is really a contest over whose model reasons best about a molecule.

It is a contest over who becomes the default place scientific work happens.
🔎 Literature search.
🧠 Hypothesis formation.
📊 Data interpretation.
🧪 Molecule ranking.
📝 Documentation of the decision.
That is a real shift, and I think it is mostly right.

I want to push on how far it travels, because science is not the same kind of prize as office work or code. The obvious objection is that pharma and hospitals will not hand proprietary, regulated data to an outside platform.
That objection is already half-answered.
Claude Science and its peers are built to run on the institution's own infrastructure, a lab's laptop, its cluster, its HPC login node, so raw data does not have to leave.
The custody problem is being engineered away.

What is not being engineered away, at least not yet, is validation.
A computational result that ends up in a regulatory submission has to survive an audit years later, by someone who was not in the room and does not trust the platform by default.
Literature synthesis and early triage are winnable now because they are low-stakes and reversible.
Nobody has shown they can win the decision that gets filed with a regulator, and that will not be won by whichever model reasons best.
It will be won by whichever platform can produce a record an inspector actually trusts.

I work close to that layer, healthcare data validation, compliance-adjacent pipelines, and the thing I keep noticing is that intelligence was never the contested resource.

𝗧𝗵𝗲 𝗿𝗲𝗰𝗼𝗿𝗱 𝗼𝗳 𝗵𝗼𝘄 𝗮 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝘄𝗮𝘀 𝗿𝗲𝗮𝗰𝗵𝗲𝗱 𝗮𝗹𝘄𝗮𝘆𝘀 𝘄𝗮𝘀.

Comments

Curated Compendium of Drug Discovery

Drug discovery is a multidisciplinary process that integrates biology, chemistry, pharmacology , and cutting-edge technologies to identify and develop new therapeutic agents. From target identification to lead optimization and clinical evaluation, each stage requires precision, innovation, and collaboration. A curated list of drug discovery resources provides researchers, students, and professionals with a structured pathway to explore advancements, tools, and strategies that shape modern therapeutics. This compilation serves as a gateway to understanding the evolution of drug discovery, recent breakthroughs, and future directions, fostering knowledge-sharing and accelerating translational research. Databases and Chemical Libraries General Compound Libraries DrugBank - Comprehensive data on approved and investigational drugs. ZINC - Free compounds for screening. ChemSpider - Chemical structures and data. DrugSpaceX - Chemical and biological spaces. Mcule ...

Understanding NMR Spectroscopy and Chemical Shift Ranges for Functional Groups

Nuclear Magnetic Resonance ( NMR ) spectroscopy is one of the most powerful analytical tools in pharmaceutical chemistry. It helps chemists determine the structure, purity, and chemical environment of molecules by analyzing the behavior of nuclei (commonly ¹H or ¹³C ) when exposed to a strong magnetic field. In proton NMR ( ¹H-NMR ), the chemical shift (δ, in ppm) provides information about the type of hydrogen atoms present in a compound and their surrounding electronic environment. Depending on nearby atoms and functional groups, signals appear in specific regions of the spectrum — often referred to as upfield (shielded, lower δ values) or downfield (deshielded, higher δ values). The image above summarizes the characteristic δ ranges for different functional groups in ¹H-NMR. Let us break it down systematically: 1. Downfield Region (δ 12 – 6 ppm) Hydrogens in this region are strongly deshielded due to electronegative atoms or π-bond systems. Carboxylic Acids (–COOH) : δ 1...

Pushing the boundaries of computational drug discovery at Isomorphic Labs

The Isomorphic Labs Drug Design Engine (IsoDDE) has unlocked a new frontier in in-silico drug design, representing a significant evolution beyond AlphaFold 3. What IsoDDE delivers: 🔹 Massive accuracy leap on unconstrained structure prediction The engine more than doubles AlphaFold 3's accuracy on extremely challenging protein-ligand prediction tasks — including systems far outside the training distribution. 🔹 Best-in-class binding affinity prediction IsoDDE predicts how strongly small molecules bind to targets with accuracy that exceeds gold-standard physics-based methods, at a fraction of the computational cost and time. 🔹 Blind identification of novel binding pockets Even without existing structural data, the engine reveals previously unseen binding sites — just from an amino acid sequence — enabling drug designers to explore entirely new chemical action spaces. 🔹 Expanded support for complex biologics Beyond small molecules, the engine boosts prediction fidelity for...

NEOPHARMA NUTSHELL COMMUNITY

Search This Blog